Cone Health Women's Hospital

MedStar Health Researchers Examine Alleged Misrepresentation of EHR Capabilities with Potentially Far-Reaching Patient Safety Implications

Retrieved on: 
Vendredi, novembre 11, 2022

COLUMBIA, Md., Nov. 11, 2022 /PRNewswire/ -- Researchers at MedStar Health, Brigham and Women's Hospital, and the University of Utah found electronic health record (EHR) vendor misconduct may have led to widespread use of suboptimal products for more than 70,000 clinicians across the country, as published today in JAMA Health Forum. Six EHR vendors were involved in settlements with U.S. Department of Health and Human Services Office of Inspector General and the U.S. Department of Justice alleging kickbacks and misrepresentation of product capabilities.

Key Points: 
  • A research letter available today in JAMA Health Forum advocates for more rigorous safety practices among EHR vendors.
  • Six EHR vendors were involved in settlements with U.S. Department of Health and Human Services Office of Inspector General and the U.S. Department of Justice alleging kickbacks and misrepresentation of product capabilities.
  • , vice president of scientific affairs for MedStar Health Research Institute, director for the MedStar Health National Center for Human Factors in Healthcare and senior author on this paper.
  • Electronic Health Record Legal Settlements in the US Since the 2009 Health Information Technology for Economic and Clinical Health Act.

Workflow Services Names Nancy Gagliano, MD as Advisor

Retrieved on: 
Jeudi, novembre 10, 2022

MADISON, Wis., Nov. 10, 2022 /PRNewswire/ -- Workflow Services, a comprehensive and automated platform that solves point-of-care clinical service delivery for pharmacies, today announced that Nancy Gagliano, MD has been named Advisor.

Key Points: 
  • MADISON, Wis., Nov. 10, 2022 /PRNewswire/ -- Workflow Services, a comprehensive and automated platform that solves point-of-care clinical service delivery for pharmacies, today announced that Nancy Gagliano, MD has been named Advisor.
  • Dr. Nancy Gagliano joins Workflow Services as an Advisor.
  • Dr. Gagliano joins Workflow Services as an accomplished physician and healthcare executive and will further position Workflow Services to deliver strong financial, clinical, and operational performance as it continues its growth and expansion.
  • Workflow Services is a healthcare software that innovates seamless point-of-care medical workflow software solutions for healthcare professionals and patients.

MiNK Therapeutics Reports Corporate Update and Third Quarter 2022 Financial Results

Retrieved on: 
Jeudi, novembre 3, 2022

NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today reported financial results for the third quarter 2022 and provided a corporate update.

Key Points: 
  • - R&D Day on November 10, 2022, from 4:00-6:00pm ET in Boston and via webcast
    NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc ., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today reported financial results for the third quarter 2022 and provided a corporate update.
  • This progress is exemplified in the five upcoming presentations at this years SITC conference and our upcoming R&D Day.
  • Individuals interested in attending the event in-person should contact MiNK Therapeutics Investor Relations at [email protected].
  • We ended the third quarter 2022 with a cash balance of$24.2 million as compared to $38.9 millionatDecember 31, 2021.

Midi Health Secures $14M Investment To Bring Expert Midlife Care for Women 40+

Retrieved on: 
Jeudi, octobre 27, 2022

SAN FRANCISCO, Oct. 27, 2022 /PRNewswire/ -- Midi Health, a virtual care clinic making expert care accessible and affordable for all women experiencing the hormonal changes of midlife, today announced the completion of a $14 million seed investment co-led by Felicis and SemperVirens. Additional investment comes from leading women's health investors including Emerson Collective, Icon Ventures, Operator Collective, Muse Capital, Steel Sky Ventures and Anne and Susan Wojcicki. Currently providing insurance covered care for patients in California, Midi will leverage the new capital to expand operations nationwide and launch partnerships with some of the largest hospital systems in the country, as well as major U.S. employers.

Key Points: 
  • Midi closes this midlife care gap with virtual care guided by nationally recognized physicians and researchers who oversee a network of nurse practitioners trained in women's midlife health.
  • "Healthcare for women aged 40+ is one of the largest segments of healthcare that has not been transformed by digital health.
  • Midi Health is the only comprehensive virtual care clinic for women navigating midlife hormonal transition.
  • Midi supports women with expert care and hormonal and non-hormonal medications, supplements, lifestyle coaching, and vital preventative health guidance.

Finch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile Infection

Retrieved on: 
Lundi, octobre 24, 2022

Finch also announced today that the company has proceeded with patient dosing in PRISM4, a Phase 3 trial of CP101 for the prevention of recurrent CDI.

Key Points: 
  • Finch also announced today that the company has proceeded with patient dosing in PRISM4, a Phase 3 trial of CP101 for the prevention of recurrent CDI.
  • These results further our understanding of the pharmacokinetics and pharmacodynamics of CP101 and support our efforts to optimize engraftment of CP101 microbes.
  • Higher engraftment of CP101-associated taxa and improvement in diversity were both associated with prevention of CDI recurrence through week 8.
  • PRISM-EXT was a Phase 2, multi-center, open-label trial of CP101 for the prevention of recurrent CDI in adults with one or more CDI recurrences.

Synapse Medicine Initiates Multi-Site Implementation Study with Leading U.S Hospitals

Retrieved on: 
Jeudi, octobre 6, 2022

The Synapse Medicine medication reconciliation tool will be deployed through an integration with the hospitals' current EPIC EHR workflow.

Key Points: 
  • The Synapse Medicine medication reconciliation tool will be deployed through an integration with the hospitals' current EPIC EHR workflow.
  • The study, "Effect of Synapse Medicine Decision Support on Inpatient Pharmacist Efficacy and Efficiency: A Hybrid Type 2 Implementation Study," engages hospital pharmacists at two study sites who round with general medicine service teams and approve inpatient medications.
  • Participants will use Synapse Medicine point-of-care tools to analyze drug-related risks and optimize medication appropriateness.
  • The study will measure the usability of Synapse Medicine AI-driven clinical decision support and medication reconciliation tools quantitatively and qualitatively to determine their impact.

Synapse Medicine Initiates Multi-Site Implementation Study with Leading U.S Hospitals

Retrieved on: 
Jeudi, octobre 6, 2022

The Synapse Medicine medication reconciliation tool will be deployed through an integration with the hospitals' current EPIC EHR workflow.

Key Points: 
  • The Synapse Medicine medication reconciliation tool will be deployed through an integration with the hospitals' current EPIC EHR workflow.
  • The study, "Effect of Synapse Medicine Decision Support on Inpatient Pharmacist Efficacy and Efficiency: A Hybrid Type 2 Implementation Study," engages hospital pharmacists at two study sites who round with general medicine service teams and approve inpatient medications.
  • Participants will use Synapse Medicine point-of-care tools to analyze drug-related risks and optimize medication appropriateness.
  • The study will measure the usability of Synapse Medicine AI-driven clinical decision support and medication reconciliation tools quantitatively and qualitatively to determine their impact.

EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports H1 2022 Financial Results and Highlights Operational Progress

Retrieved on: 
Vendredi, septembre 30, 2022

Firstly, we have been able to further de-risk clinical development of varoglutamstat with extremely encouraging safety results from our VIVIAD Phase 2b study.

Key Points: 
  • Firstly, we have been able to further de-risk clinical development of varoglutamstat with extremely encouraging safety results from our VIVIAD Phase 2b study.
  • Vivoryon presented detailed safety data from the VIVIAD study at the Alzheimers Association International Conference (AAIC) in San Diego (July 31 to August 4, 2022).
  • On June 22, 2022, Vivoryon held its Annual General Meeting where all voting items were approved with a large majority.
  • Condensed Statements of Profit or Loss and Other Comprehensive Income for the six months ended June 30, 2022 and 2021

Edgar Ross, M.D., Renowned Pain Expert and Director of Pain Management at Harvard University, Joins Harvard MedTech’s Medical Advisory Board

Retrieved on: 
Mardi, septembre 27, 2022

Edgar Ross, M.D., one of the nation's most renowned pain experts, is joining the Medical Advisory Board of Harvard MedTech .

Key Points: 
  • Edgar Ross, M.D., one of the nation's most renowned pain experts, is joining the Medical Advisory Board of Harvard MedTech .
  • We are honored to have one of the nations foremost authorities on pain management join Harvard MedTechs Medical Advisory Board, said Gerry Stanley, M.D., Chief Medical Officer, Harvard MedTech.
  • Like Harvard MedTech, he is committed to reversing the opioid crisis and ensuring non-addictive treatments become more mainstream in the management of injured workers.
  • Dr. Ross is considered one of the leading pain management physicians in the world and is recognized for his contributions to the field of pain management across the globe.

Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors

Retrieved on: 
Lundi, septembre 26, 2022

FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced the appointment of James Jamie Topper, M.D., Ph.D., to its Board of Directors.

Key Points: 
  • FLORHAM PARK, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced the appointment of James Jamie Topper, M.D., Ph.D., to its Board of Directors.
  • Dr. Topper is rejoining Phathoms Board having served as a Phathom Board member from its creation in January 2018 until May 2021.
  • Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders.
  • For more information about Phathom, visit the Companys website at www.phathompharma.com and follow the Companyon LinkedIn and Twitter .